Hankang Capital

Hankang Capital is a Beijing-based venture firm investing in healthcare companies, with a focus on biotech and pharma and therapeutics. The firm engages founders and management teams advancing scientifically rigorous programs in drug discovery, biologics, and adjacent therapeutic platforms, supporting them through clinical development and regulatory advancement. Its Beijing base places it at the center of China’s biopharma research ecosystem, with proximity to leading academic institutions, contract research organizations, and the regulatory community. Specific portfolio companies and named partners are not provided in the input, so this profile reflects the firm’s stated focus rather than individual investments.

Hankang Capital writes checks in the $5M to $25M range and invests across Series A, Series B, and Series C rounds. Headquartered in China, its primary geography reflects the Chinese biopharma market and globally relevant programs developed there. The mid- to growth-stage focus means the firm typically engages after early scientific validation and supports companies as they advance through clinical milestones and toward commercialization.

For founders and management teams, Hankang is most relevant when a biotech or pharma program has clear scientific differentiation, a credible clinical development plan, and meaningful relevance to the Chinese market. The firm prefers teams that engage rigorously on data, regulatory strategy, and operational execution. Founders should expect direct conversations about clinical milestones, capital requirements across long development arcs, and the strategic role China plays in a program’s overall global plan, with a partner that can navigate the local regulatory and capital environment.